

B<sup>1</sup>  
cont'd

reductase [inhibitor] or an inhibitor of any subtype of [that enzyme] 5  
alpha reductase enzyme resulting in decreased levels of  
dihydrotestosterone (DHT), in an amount sufficient to reduce  
atherosclerosis.

B<sup>2</sup>

Insert as a new paragraph at the beginning of the Specification - - [This is a  
continuation of provisional Application Serial No. 60/041,070, filed March 18, 1997. ~

B<sup>3</sup>

Page 4, line 15, change "Leuprolide or Goserelin" to - - [leuprolide acetate or  
goserelin acetate ~.

B<sup>4</sup>

Page 5, in the table, first column, please change the parenthetical phrases  
after Group 2, Group 3 and Group 5 to read - - [leuprolide acetate (after Group 2) and  
goserelin acetate (below Group 3)

#### REMARKS

The various changes required by the Examiner have been made. Also, a  
terminal disclaimer is being provided as requested in the Office Action. Accordingly, it is  
submitted that this patent application is now in condition for allowance.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,  
COHEN & POKOTILOV, LTD.

May 1, 2000

By



Alan H. Bernstein

Reg. No. 19,315

12th Floor, Seven Penn Center

1635 Market Street

Philadelphia, PA 19103-2212

Attorneys for Applicant